CCL5 and graft versus host disease: Secondly, our study describes the previously unknown immunomodulatory effects of Dara in the mitigation of GVHD by the reduced expression of cytotoxic effector molecules (Granzyme A, Granzyme B, Granulysin, Perforin 1), pro-inflammatory cytokines (IL15, IL32, IFNγ, IL6, IL10), chemokines and chemoattractant receptors (CX3CR1, CXCR3, CCR1, CCR2, CCR5, CCL3, CCL4, CCL5) by T cells.